$MLAB

Tripeny R Tony purchased $102K of MLAB

Tripeny R Tony purchased 900 shares of MESA LABORATORIES INC /CO/ (MLAB) at $113.69 ($0.10M total) on 2026-08-13.

Original reporting
SEC EDGAR · Tripeny R Tony
Published Aug 17, 2026, 3:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 3:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MLAB
Bullish
medium confidence
Mentioned
$MLAB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABBullishLow
01

Why it matters

The director’s open-market purchase at $113.69 is a bullish signal, but the disclosed dollar value is relatively small and does not include any new company fundamentals.

02

Market read

Traders may note insider accumulation, but the filing alone is unlikely to drive a major repricing without accompanying operational or financial catalysts.

03

What to watch

The article does not state whether the director has other holdings changes, motivations, or any concurrent company-specific catalysts (earnings, guidance, contracts).

Relevance 5/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

This is an SEC Form 4 insider transaction disclosure for MESA Laboratories Inc (MLAB).

Company-level read

Ticker impact

$MLABBullishMedium confidence
Context

Tripeny R Tony, a MESA Laboratories director, bought 900 shares of MLAB in an open-market transaction at $113.69 on 2026-08-13.

Expected impact

Likely minimal near-term price impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider purchases can be read as bullish, but this transaction size ($102k) and lack of 10b5-1 plan details provide limited incremental information versus earnings, guidance, or major corporate events.

Market effects

No sector-wide signal; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification actions and do not necessarily reflect near-term business improvement.

Key entities

  • MLAB

    MESA Laboratories Inc, the company whose director transaction is disclosed.

  • Tripeny R Tony

    Director of MESA Laboratories who purchased 900 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MLABMedAI 8/10

Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million…

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth The Restructuring Program focuses Clinical Genomics on profitability and adds resources in

$MLABMedAI 8/10

Mesa Laboratories (MLAB) Q1 2027 Earnings Call Transcript

Mesa Laboratories (MLAB) reported Q1 FY2027 revenues of $60.1 million, up 1% year over year, with core organic growth of 0.4%. Adjusted operating income was $15.4 million, up 19.5%, and gross margin rose to 64.9%. Net leverage fell to 1.85x after $8.7 million debt repayment. SDC revenue was $24.5 million, down 3.6% organically.

$MLABMed

Mesa Labs Announces First Quarter Results

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado , August 10, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announc

$MLABHighAI 9/10

Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

Mesa Laboratories (NASDAQ:MLAB) reported 4Q26 revenues up 2.6% to $63.7M and FY26 revenues up 3.4% to $249.1M. Operating income rose 87% to $2.75M in 4Q26 and 13.3% to $18.5M in FY26. Non-GAAP AOI excluding unusual items increased 49.2% (4Q26) and 11.9% (FY26); FY26 free cash flow was $39.6M, used mainly to repay $14.7M debt, reducing net leverage to 2.11.